Dermatologic findings after initiation of fingolimod in patients with multiple sclerosis: A real-world experience of five-year follow-up
{{output}}
Background: Fingolimod was approved in 2010 for the treatment of relapsing-remitting multiple sclerosis, generally as second-line therapy. While its efficacy in reducing the relapse rate is well-recognized, the dermatologic compl... ...
